Bone Marrow Transplant Rejection - Pipeline Review, H1 2020
Bone Marrow Transplant Rejection - Pipeline Review, H1 2020
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H1 2020, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape.
Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain and shortness of breath. Treatment includes immunosuppressive drugs.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 12, 39, 13, 3, 46, 5 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 12 and 1 molecules, respectively.
Bone Marrow Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection (Immunology).
- The pipeline guide reviews pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bone Marrow Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bone Marrow Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bone Marrow Transplant Rejection (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Introduction
Bone Marrow Transplant Rejection - Overview
Bone Marrow Transplant Rejection - Therapeutics Development
Bone Marrow Transplant Rejection - Therapeutics Assessment
Bone Marrow Transplant Rejection - Companies Involved in Therapeutics Development
Bone Marrow Transplant Rejection - Drug Profiles
Bone Marrow Transplant Rejection - Dormant Projects
Bone Marrow Transplant Rejection - Discontinued Products
Bone Marrow Transplant Rejection - Product Development Milestones
Appendix
Tables and Figures
List of Tables
Number of Products under Development for Bone Marrow Transplant Rejection, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Companies, H1 2020 (Contd..8), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Bone Marrow Transplant Rejection - Pipeline by AbbVie Inc, H1 2020
Bone Marrow Transplant Rejection - Pipeline by AbGenomics International Inc, H1 2020
Bone Marrow Transplant Rejection - Pipeline by Adienne Pharma & Biotech, H1 2020
Bone Marrow Transplant Rejection - Pipeline by Alpine Immune Sciences Inc, H1 2020
Bone Marrow Transplant Rejection - Pipeline by Amgen Inc, H1 2020
Bone Marrow Transplant Rejection - Dormant Projects, H1 2020
Bone Marrow Transplant Rejection - Discontinued Products, H1 2020
List of Figures
Number of Products under Development for Bone Marrow Transplant Rejection, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned
AbbVie Inc
AbGenomics International Inc
Adienne Pharma & Biotech
Alpine Immune Sciences Inc
Amgen Inc
AnaptysBio Inc
apceth Biopharma GmbH
ASC Therapeutics Inc
AstraZeneca Plc
Athersys Inc
Autolus Therapeutics Plc
Bellicum Pharmaceuticals Inc
Biocon Ltd
Biogen Inc
BioIncept LLC
BlueRock Therapeutics
Boryung ViGenCell Inc
Bristol-Myers Squibb Co
Capricor Therapeutics Inc
Cell Source Inc
Cellect Biotechnology Ltd
Cellective BioTherapy Inc
Cellix Bio Pvt Ltd
CheckPoint Immunology Inc
Clinigen Group Plc
Compugen Ltd
CSL Ltd
CTI BioPharma Corp
Cytodyn Inc
Cytopeutics Pte Ltd
Daewoong Pharmaceutical Co Ltd
Dualogics Corp
Eli Lilly and Co
Elsalys Biotech SA
enGene Inc
Enlivex Therapeutics Ltd
ExCellThera Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Forty Seven Inc
Fujifilm Holdings Corp
Generon (Shanghai) Corp Ltd
GigaGen Inc
GlaxoSmithKline Plc
Glia LLC
Humanigen Inc
Immplacate
Immune Modulation Inc
ImmuneTarget Inc
Imstem Biotechnology Inc
Incyte Corp
Inspyr Therapeutics Inc
ITB-Med AB
Jazz Pharmaceuticals Plc
JN Biosciences LLC
Kadmon Corp LLC
Kalytera Therapeutics Inc
Kamada Ltd
Kiadis Pharma NV
Kiniksa Pharmaceuticals Ltd
Kymab Ltd
LG Chem Ltd
MaaT Pharma
Machavert Pharmaceuticals LLC
Magenta Therapeutics Inc
Mallinckrodt Plc
Medac Pharma Inc
Medicenna Therapeutics Corp
Medsenic SAS
Mereo Biopharma Group Plc
Mesoblast Ltd
Millennium Pharmaceuticals Inc
NapaJen Pharma Inc
Neovii Pharmaceuticals AG
Novartis AG
Ocugen Inc
OncoImmune Inc
OSE Immunotherapeutics
Panorama Research Inc
Pfizer Inc
Pharmicell Co Ltd
Pluristem Therapeutics Inc
Precision Biosciences Inc
REGiMMUNE Corp
Sanofi
SCM lifescience Co Ltd
Seattle Genetics Inc
Secura Bio Inc
Seres Therapeutics Inc
STERO Biotechs Ltd
Suzhou Connect Biopharmaceuticals Ltd
Syndax Pharmaceuticals Inc
Synthetic Biologics Inc
Taiwan Bio Therapeutics Co Ltd
Takeda Pharmaceutical Co Ltd
Targazyme Inc
TCF GmbH
TeraImmune Inc
TGV Laboratories Inc
United BioPharma Inc
Vault Pharma Inc
VBI Vaccines Inc
Visterra Inc
Xenikos BV
Xenothera SAS
XL-protein GmbH
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets